BsAbs for Immune Cell Recruitment

Creative Biolabs is an international company with years of experience in antibody production. We have multiple well-developed BsAb engineering/ production platforms and are dedicated to providing our customers superior bispecific antibodies (BsAb) services.

The immune system is essential for human health and plays an important role in tumor prevention/ treatment. Exploiting the natural immune system of patients is an important cancer treatment strategy. As the name indicated, BsAbs can bind two or more receptors simultaneously or bring two or more targets in proximity. Specific BsAbs can retarget immune cells to tumor cells, allowing subsequent activation and proliferation of immune cells, the release of cytokines, phagocytosis, and other anti-tumor reactions that eventually eliminate tumor cells. Therefore BsAb has recently become a popular format of cancer drugs.

Figure 1. Immune cell recruitment by BsAbs.

BsAbs for Immune Cell Recruitment

T cells and Natural killer (NK) cells are two kinds of cytotoxic lymphocytes and are crucial components of the immune system. Many formats of BsAbs are designed for T cell recruitment and NK cell recruitment: tandem scFv, diabody (such as scDiabody, TandAb), etc. They bind to CD3 on T cells or CD16 (FcγRIII)/CD56 on NK cells and tumor-associated antigens on tumor cells. BsAbs with the Fc region, which recognizes Fcγ receptor (FcγR), also recruit accessory cells such as dendritic cells, natural killing cells, and macrophages. Once redirected to tumor cells, these effector cells can release cytotoxic pro-inflammatory cytokines. Eventually, tumor cells are expected to be killed by ADCC, phagocytosis, and T cell-mediated lysis.

Creative Biolabs has a professional and experienced BsAb research team with advanced antibody engineering platforms. We provide custom BsAb services including BsAb design, engineering, manufacture, and analysis.

Recommended products: Tandem scFv, diabody (such as scDiabody, TandAb), etc.

References

1. Baty D.; et al. Bispecific effector-cell engagers, novel immunotherapeutics trained to fight cancer. Medicographia. 2015, 37: 271-279.
2. Kontermann R. E.; Brinkmann, U. Bispecific antibodies. Drug Discovery Today. 2015, 20(7): 838-47.